Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXO-CD24 for Prevention of Clinical Deterioration in Moderate or Severe COVID-19 (Phase IIb)
2021-004259-17Phase 2Terminated
- Sponsor
- OBCTCD-24
- Start
- Jan 2022
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised trial in coronavirus disease 2019 (COVID-19) comparing EXO-CD24 (CovenD24) with Placebo (2 arms). Started Jan 2022; status: terminated.
02
Drugs
exosomes overexpressing CD24
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-004259-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004259-17.